Employ Artificial Intelligence to Revolutionize Drug Discovery
Deriving a data-driven principle that has the power of explaining physical and chemical nature of biological systems, which we harness to accelerate drug discoveries.
What is our philosophy
To derive a data-driven principle that has the power of explaining physical and chemical nature of biological systems, which we harness to accelerate drug discoveries.
What have we done
A data-driven atom-based scoring function is learned from 100,000 protein crystal structures containing information of >100 million amino acid side chains.
A dynamic deep neural network specifically designed for chemical informatics.
Why is our work impactful
Beating current gold standard in computation-aided drug discovery:
Drug pocket side chain conformation prediction and drug docking with significantly increased accuracy compared to standard method.
Prediction of chemical compound characteristics (solubility, binding affinity, etc) significantly better than current standard.

Recent News

Accutar Tops ongoing Kinase-drug binding affinity prediction Dream Challenge
Accutar to present at Amgen AI conference, Boston
Accutar presented at World Artificial Intelligence Conference 2018, Shanghai
Ligand docking and virtual screen for drug discovery
A video demonstrates how Orbital docking and virtual screen works.
ADME prediction aids drug development
A dynamic deep neural network specifically designed for cheminformatics.
LEADERSHIP
Dr. Jie Fan
Founder and CEO
Dr. Wei He
Chief Scientific Officer
Dr. Yimin Qian
Chief Discovery Officer and Head of Chemistry
Dr. Günter Blobel
in memoriam
Dr. Jerard Hurwitz
Dr. Jian Jin
Dr. Carlos Garcia-Echeverria
Jie Fan, Ph.D.
Founder and CEO
Dr. Fan was trained at UC, Berkeley in Biostatistics and obtained his Doctor degree from Cornell/Sloan-kettering in structural biology/Immunology. He was further trained by Dr. Gunter Blobel at Rockefeller University. With a dream of using a hybrid approach (by combining computation design and experimental validation) to accelerate drug discovery, and to reform current “hit-2-lead” drug discovery scheme, Dr. Fan founded Accutar biotech with the support of Dr. Gunter Blobel. Dr. Fan also hold a joint appointment at SUNY, Downstate medical school as a research assistant professor.
Wei He, Ph.D.
Chief Scientific Officer
Wei He, Ph.D., brings to Accutar Biotechnology 11 years of oncology drug discovery experience in both small molecule and biologics. Most recently, he was Associate Director of Preclinical Pharmacology at Incyte Corporation. In this role, he oversaw cancer biology groups leading efforts of project initiation and progression to IND. Prior to joining Incyte, Wei served as scientific project leader at Abbvie Oncology and Roche Oncology, where he led cross-functional project teams working on immuno oncology, targeted therapy, antibody drug conjugate and therapeutic RNAi programs.
Wei obtained his B.S. and M.S. in chemistry from Peking University in China and his Ph.D. in biochemistry and molecular biology from Baylor College of Medicine. He completed his HHMI postdoctoral training at the Memorial Sloan-Kettering Cancer Center.
Günter Blobel, MD, Ph.D.
Rockefeller University
Dr. Blobel is a member of National academy of sciences and is recognized by numerous awards including Nobel Prize in physiology and medicine (1999) and Albert Lasker Award for Basic Medical Research (1993). He served as selection committee member for prestigious Lasker award, Shaw prize and Wiley prize etc. He also sits on board of directors for Nestle and Board of Scientific Governors at The Scripps Research Institute.
Jerard Hurwitz, Ph.D.
Memorial Sloan-kettering Institute
Dr. Hurwitz is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. His notable awards include: the Eli Lilly Award in Biological Chemistry, the Institut Pasteur Hazen Lectureship, and the New York Academy of Science's Louis and Bert Freeman Foundation Prize for Research in Biochemistry.
Jian Jin, Ph.D.
Icahn School of Medicine at Mount Sinai
Dr. Jin is a Professor of Structural & Chemical Biology , Oncological Sciences , Pharmacology & Systems Therapeutics at Mount Sinai. Before being recruited to Mount Sinai, Dr. Jin served as an Associate Director of medicinal chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC – CH from 2008 to 2014. Dr. Jin has published more than 100 research papers and delivered 69 invited talks. He is also an inventor of 10 issued U.S. patents and 37 published PCT patent applications.
Yimin Qian, Ph.D.
Chief Discovery Officer and Head of Chemistry
Yimin Qian, Ph.D., brings to Accutar Biotechnology over 20 years of drug discovery experiences in both Pharma and Biotech. Yimin held multiple leadership positions previously. Most recently, he was Senior Director at Arvinas (2014-2018), Director & Asian lead at Merck (2013-2014) and Research Leader at Roche (1997-2013). Yimin has published over 50 peer reviewed papers with over 3000 scientific citations. Yimin is an inventor of 29 issued U.S. patents and additional 26 pending patent applications. At Accutar, Yimin will lead efforts to train AI drug discovery platform using expert human knowledge and to further improve Accutar-Degrader (Accurate-target degrader) technology platform. Yimin obtained Ph.D. degree in organic chemistry from University of Pittsburgh. He received post-doc training from Yale University.
Carlos Garcia-Echeverria, Ph.D.
Sanofi
Carlos Garcia-Echeverria, Ph.D. has served as Global Head of Research Platforms at Sanofi since January 2016. Previously, he was Global Head of Small Molecule Drug Discovery (2014-2016) and Deputy Global Head of Oncology Drug Discovery and Preclinical Development (April 2010-2014). From 1993 to 2010, Dr. Garcia-Echeverria held several positions of increasing responsibility at the Novartis Institutes for BioMedical Research. In his last position as Executive Director of Oncology Drug Discovery, he was responsible for managing the late drug discovery programs at the Novartis Oncology Research site in Basel, Switzerland. His research activities have been mainly focused on the identification and development of inhibitors of protein and lipid kinases, proteolytic enzymes and antagonists of intracellular protein-protein interactions. Dr Garcia-Echeverria received the Leonidas Zervas Award from the European Peptide Society in 2006, and has made significant contributions to the identification and development of targeted cancer therapies advancing more than fifteen drug candidates to clinical trials. He is an inventor on over 40 patents, and has published more than 180 peer-reviewed articles, book chapters and review papers. Co-editor of “The Drug Annotations Series” (Journal of Medicinal Chemistry, ACS) and past-senior editor of “Chemical Biology & Drug Design”. Invited Associate Professor – School of Pharmacy, SKUU University, Seoul, South Korea (2007-2011). Dr Garcia-Echeverria received his Ph.D. in organic chemistry from the University of Barcelona (Spain) in 1990.
INVESTORS